Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
ETHAN - ET for Male BC
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jose Pablo Leone
- Target Recruit Count
- 60
- Registration Number
- NCT05501704
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Oana Danciu
- Target Recruit Count
- 200
- Registration Number
- NCT05467891
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Phoenix, Arizona, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Drug: AlectinibDrug: AlpelisibDrug: AnastrozoleBiological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CapecitabineDrug: CarboplatinDrug: CobimetinibDrug: EntrectinibDrug: EribulinDrug: FulvestrantBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabDrug: IrinotecanDrug: LetrozoleDrug: Nab-paclitaxelDrug: NiraparibDrug: OlaparibDrug: PaclitaxelDrug: PalbociclibBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab EmtansineDrug: VemurafenibDrug: VinorelbineDrug: Vismodegib
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Roll-over Study to Allow Continued Access to Ribociclib
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT05161195
- Locations
- 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 1100
- Registration Number
- NCT04985266
- Locations
- 🇬🇧
Barnet Hospital, London, Barnet, United Kingdom
🇬🇧Royal Sussex Hospital, Brighton, United Kingdom
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT04964934
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.
- Conditions
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 9
- Registration Number
- NCT04757532
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
- Conditions
- Refractory Endometrial AdenocarcinomaRefractory Endometrial CarcinomaRefractory Endometrial Serous AdenocarcinomaRefractory Endometrial Mixed Cell AdenocarcinomaRefractory Endometrial Undifferentiated CarcinomaRefractory Endometrial Clear Cell AdenocarcinomaRefractory Endometrial Endometrioid Adenocarcinoma
- Interventions
- Drug: Extended-release OnapristoneDrug: AnastrozoleOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationDiagnostic Test: Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)Diagnostic Test: Progesterone Receptor Positive ( PGR Positive; PR Positive)
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 14
- Registration Number
- NCT04719273
- Locations
- 🇺🇸
Jefferson Abington Hospital, Abington, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1370
- Registration Number
- NCT04711252
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.